These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Antibody-Targeted Cyclodextrin-Based Nanoparticles for siRNA Delivery in the Treatment of Acute Myeloid Leukemia: Physicochemical Characteristics, in Vitro Mechanistic Studies, and ex Vivo Patient Derived Therapeutic Efficacy. Guo J; Russell EG; Darcy R; Cotter TG; McKenna SL; Cahill MR; O'Driscoll CM Mol Pharm; 2017 Mar; 14(3):940-952. PubMed ID: 28146632 [TBL] [Abstract][Full Text] [Related]
3. Systematic evaluation of antibody-mediated siRNA delivery using an industrial platform of THIOMAB-siRNA conjugates. Cuellar TL; Barnes D; Nelson C; Tanguay J; Yu SF; Wen X; Scales SJ; Gesch J; Davis D; van Brabant Smith A; Leake D; Vandlen R; Siebel CW Nucleic Acids Res; 2015 Jan; 43(2):1189-203. PubMed ID: 25550431 [TBL] [Abstract][Full Text] [Related]
4. Targeting CXCR4/SDF-1 axis by lipopolymer complexes of siRNA in acute myeloid leukemia. Landry B; Gül-Uludağ H; Plianwong S; Kucharski C; Zak Z; Parmar MB; Kutsch O; Jiang H; Brandwein J; Uludağ H J Control Release; 2016 Feb; 224():8-21. PubMed ID: 26742943 [TBL] [Abstract][Full Text] [Related]
5. Development of antibody-siRNA conjugate targeted to cardiac and skeletal muscles. Sugo T; Terada M; Oikawa T; Miyata K; Nishimura S; Kenjo E; Ogasawara-Shimizu M; Makita Y; Imaichi S; Murata S; Otake K; Kikuchi K; Teratani M; Masuda Y; Kamei T; Takagahara S; Ikeda S; Ohtaki T; Matsumoto H J Control Release; 2016 Sep; 237():1-13. PubMed ID: 27369865 [TBL] [Abstract][Full Text] [Related]
6. Antibody-siRNA conjugates (ARCs) using multifunctional peptide as a tumor enzyme cleavable linker mediated effective intracellular delivery of siRNA. Yu Z; Zhang X; Pei X; Cao W; Ye J; Wang J; Sun L; Yu F; Wang J; Li N; Lee K; Barth S; Yang VC; He H Int J Pharm; 2021 Sep; 606():120940. PubMed ID: 34310959 [TBL] [Abstract][Full Text] [Related]
7. Site Selective Antibody-Oligonucleotide Conjugation via Microbial Transglutaminase. Huggins IJ; Medina CA; Springer AD; van den Berg A; Jadhav S; Cui X; Dowdy SF Molecules; 2019 Sep; 24(18):. PubMed ID: 31509944 [TBL] [Abstract][Full Text] [Related]
9. Therapeutic targeting of gene expression by siRNAs directed against BCR-ABL transcripts in a patient with imatinib-resistant chronic myeloid leukemia. Koldehoff M; Elmaagacli AH Methods Mol Biol; 2009; 487():451-66. PubMed ID: 19301661 [TBL] [Abstract][Full Text] [Related]
10. Exploring cell type-specific internalizing antibodies for targeted delivery of siRNA. Liu B Brief Funct Genomic Proteomic; 2007 Jun; 6(2):112-9. PubMed ID: 17670766 [TBL] [Abstract][Full Text] [Related]
11. WT1 and BCR-ABL specific small interfering RNA have additive effects in the induction of apoptosis in leukemic cells. Elmaagacli AH; Koldehoff M; Peceny R; Klein-Hitpass L; Ottinger H; Beelen DW; Opalka B Haematologica; 2005 Mar; 90(3):326-34. PubMed ID: 15749664 [TBL] [Abstract][Full Text] [Related]
12. Targeting bcr-abl transcripts with siRNAs in an imatinib-resistant chronic myeloid leukemia patient: challenges and future directions. Koldehoff M Methods Mol Biol; 2015; 1218():277-92. PubMed ID: 25319658 [TBL] [Abstract][Full Text] [Related]
14. Targeted delivery of SiRNA to CD33-positive tumor cells with liposomal carrier systems. Rothdiener M; Müller D; Castro PG; Scholz A; Schwemmlein M; Fey G; Heidenreich O; Kontermann RE J Control Release; 2010 Jun; 144(2):251-8. PubMed ID: 20184933 [TBL] [Abstract][Full Text] [Related]
15. Silencing of myeloid cell leukemia-1 by small interfering RNA improves chemosensitivity to etoposide in u-937 leukemic cells. Jafarlou M; Baradaran B; Shanehbandi D; Saedi TA; Jafarlou V; Karimi P; Othman F J Biol Regul Homeost Agents; 2016; 30(1):55-65. PubMed ID: 27049076 [TBL] [Abstract][Full Text] [Related]
16. Antibody-drug therapeutic conjugates: Potential of antibody-siRNAs in cancer therapy. Yarian F; Alibakhshi A; Eyvazi S; Arezumand R; Ahangarzadeh S J Cell Physiol; 2019 Aug; 234(10):16724-16738. PubMed ID: 30908646 [TBL] [Abstract][Full Text] [Related]
17. Conjugates of HA2 with octaarginine-grafted HPMA copolymer offer effective siRNA delivery and gene silencing in cancer cells. Golan M; Feinshtein V; David A Eur J Pharm Biopharm; 2016 Dec; 109():103-112. PubMed ID: 27702685 [TBL] [Abstract][Full Text] [Related]
18. Biodegradable charged polyester-based vectors (BCPVs) as an efficient non-viral transfection nanoagent for gene knockdown of the BCR-ABL hybrid oncogene in a human chronic myeloid leukemia cell line. Yang C; Panwar N; Wang Y; Zhang B; Liu M; Toh H; Yoon HS; Tjin SC; Chong PH; Law WC; Chen CK; Yong KT Nanoscale; 2016 Apr; 8(17):9405-16. PubMed ID: 27092903 [TBL] [Abstract][Full Text] [Related]
19. Delivery of therapeutic shRNA and siRNA by Tat fusion peptide targeting BCR-ABL fusion gene in Chronic Myeloid Leukemia cells. Arthanari Y; Pluen A; Rajendran R; Aojula H; Demonacos C J Control Release; 2010 Aug; 145(3):272-80. PubMed ID: 20403398 [TBL] [Abstract][Full Text] [Related]